Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3%, currently at 3.25 HKD, following the announcement of the successful administration of the first patient in a multi-dose escalation (MAD) Phase Ib trial for HMS1005, a second-generation glucose kinase activator [1][2]. Group 1: Clinical Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) subjects in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1]. Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow for once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1]. - The drug aims to improve the repair capacity of patients with insufficient GLP-1 secretion [1]. Group 3: Future Plans - Following the successful completion of the MAD Ib study, the company plans to seek partners for the global development of HMS1005 [2].
港股异动 华领医药-B(02552)涨超3% 第二代GKA美国MAD Ib期试验成功给药 未来拟寻求合作伙伴